The U.S. Food and Drug Administration (FDA) has released information regarding import refusals in June indicating that 5 out of the 118 (4.2%) total seafood entry line refusals last month were of shrimp for reasons related to banned antibiotics.
Through the first half of this year, the FDA has now reported refusing a total of 25 entry lines of shrimp for reasons related to veterinary drug residues:
The five shrimp entry line refusals in June were from exporters in two different countries – India and China – and involved two different FDA regional districts:
Dongguan Ateier Import and Export Co., Ltd. (China), a company that has not been exempted from Import Alert 16-131 (“Detention Without Physical Examination of Aquacultured Shrimp, Dace, and Eel from China – Presence of New Animal Drugs and/or Unsafe Food Additives”), had three entry lines refused for shrimp contaminated with veterinary drug residues and unsafe additives by the Division of Northeast Imports on June 7, 2018; and
Kader Exports Private Limited (India), a company that was added to Import Alert 16-127 (“Detention Without Physical Examination of Crustaceans Due to Chloramphenicol”) on June 5, 2018, had two entry lines refused for shrimp contaminated with veterinary drug residues by the Division of Southeast Imports on June 13, 2018.
Source: Southern Shrimp Alliance
